Quest Diagnostics Incorporated (NYSE:DGX) had its price objective boosted by equities research analysts at Morgan Stanley from $87.00 to $92.00 in a research note issued on Thursday. The firm presently has an “underweight” rating on the medical research company’s stock. Morgan Stanley’s price objective indicates a potential downside of 12.89% from the company’s current price.

DGX has been the subject of several other research reports. UBS AG restated a “buy” rating and set a $115.00 price target (up previously from $102.00) on shares of Quest Diagnostics in a research report on Tuesday, April 25th. Zacks Investment Research raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $122.00 price objective for the company in a research note on Tuesday, June 6th. Mizuho reaffirmed a “buy” rating and set a $90.00 price objective (down previously from $103.00) on shares of Quest Diagnostics in a research note on Friday, April 14th. BidaskClub raised shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 29th. Finally, ValuEngine raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Friday, June 2nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $109.62.

Shares of Quest Diagnostics (NYSE DGX) traded down 0.84% on Thursday, hitting $105.61. The stock had a trading volume of 689,526 shares. Quest Diagnostics has a 12 month low of $79.12 and a 12 month high of $112.97. The firm has a market cap of $14.41 billion, a P/E ratio of 21.28 and a beta of 0.69. The firm’s 50-day moving average price is $109.02 and its 200 day moving average price is $102.91.

Quest Diagnostics (NYSE:DGX) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.13. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.94 billion. During the same quarter in the prior year, the firm earned $1.34 EPS. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. Analysts anticipate that Quest Diagnostics will post $5.70 EPS for the current fiscal year.

WARNING: “Quest Diagnostics Incorporated (DGX) Given New $92.00 Price Target at Morgan Stanley” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/08/10/quest-diagnostics-incorporated-dgx-given-new-92-00-price-target-at-morgan-stanley.html.

In other news, Director Jeffrey M. Leiden sold 296 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $106.66, for a total value of $31,571.36. Following the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $639,960. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey M. Leiden sold 1,304 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $108.73, for a total transaction of $141,783.92. Following the completion of the transaction, the director now owns 6,296 shares in the company, valued at $684,564.08. The disclosure for this sale can be found here. In the last three months, insiders sold 61,362 shares of company stock valued at $6,600,758. Corporate insiders own 1.50% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Fiera Capital Corp bought a new position in shares of Quest Diagnostics during the second quarter valued at approximately $304,000. Summit Global Investments raised its position in shares of Quest Diagnostics by 12.2% in the second quarter. Summit Global Investments now owns 4,600 shares of the medical research company’s stock valued at $511,000 after buying an additional 500 shares in the last quarter. Riverhead Capital Management LLC raised its position in shares of Quest Diagnostics by 84.9% in the second quarter. Riverhead Capital Management LLC now owns 68,495 shares of the medical research company’s stock valued at $7,614,000 after buying an additional 31,441 shares in the last quarter. AJO LP raised its position in shares of Quest Diagnostics by 137.9% in the second quarter. AJO LP now owns 2,134,245 shares of the medical research company’s stock valued at $237,243,000 after buying an additional 1,237,021 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Quest Diagnostics by 3.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,894 shares of the medical research company’s stock valued at $434,000 after buying an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 90.97% of the company’s stock.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.